Bioventus (BVS) Revenue (2020 - 2026)

Bioventus has reported Revenue for 7 years, with the latest figure at $132.1 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 6.63% year-over-year to $132.1 million; the trailing twelve-month figure through Mar 2026 stood at $576.3 million (up 1.52% YoY), and the FY2025 full-year result was $568.1 million, down 0.91% from the prior year.
• Revenue for Q1 2026 stood at $132.1 million, down from $157.9 million in the prior quarter.
• The five-year high for Revenue was $157.9 million in Q4 2025, with the low at $117.3 million in Q2 2022.
• Historically, Revenue has averaged $135.2 million across 5 years, with a median of $135.4 million in 2023.
• Annual changes were most pronounced in 2022 — Revenue jumped 43.42% — and 2023, when it retreated 6.12%.
• Bioventus' Revenue stood at $125.8 million in 2022, then advanced by 7.62% to $135.4 million in 2023, then gained by 13.45% to $153.6 million in 2024, then gained by 2.77% to $157.9 million in 2025, then slipped by 16.35% to $132.1 million in 2026.
• The last three Revenue figures came in at $132.1 million (Q1 2026), $157.9 million (Q4 2025), and $138.7 million (Q3 2025), per Business Quant data.